Ligand Pharmaceuticals Incorporated

DB:LGDN Stock Report

Market Cap: €2.1b

Ligand Pharmaceuticals Management

Management criteria checks 3/4

Ligand Pharmaceuticals' CEO is Todd Davis, appointed in Dec 2022, has a tenure of 17.75 years. total yearly compensation is $6.22M, comprised of 10.5% salary and 89.5% bonuses, including company stock and options. directly owns 0.42% of the company’s shares, worth €8.71M. The average tenure of the management team and the board of directors is 2 years and 15.1 years respectively.

Key information

Todd Davis

Chief executive officer

US$6.2m

Total compensation

CEO salary percentage10.5%
CEO tenure2yrs
CEO ownership0.4%
Management average tenure2yrs
Board average tenure15.1yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Todd Davis's remuneration changed compared to Ligand Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

US$45m

Jun 30 2024n/an/a

US$42m

Mar 31 2024n/an/a

US$96m

Dec 31 2023US$6mUS$650k

US$54m

Sep 30 2023n/an/a

US$21m

Jun 30 2023n/an/a

US$41m

Mar 31 2023n/an/a

US$51m

Dec 31 2022US$6mUS$49k

-US$5m

Sep 30 2022n/an/a

US$23m

Jun 30 2022n/an/a

US$27m

Mar 31 2022n/an/a

US$45m

Dec 31 2021US$328kn/a

US$76m

Sep 30 2021n/an/a

US$68m

Jun 30 2021n/an/a

US$48m

Mar 31 2021n/an/a

US$39m

Dec 31 2020US$329kn/a

US$7m

Sep 30 2020n/an/a

-US$16m

Jun 30 2020n/an/a

-US$25m

Mar 31 2020n/an/a

-US$61m

Dec 31 2019US$350kn/a

US$629m

Sep 30 2019n/an/a

US$594m

Jun 30 2019n/an/a

US$677m

Mar 31 2019n/an/a

US$764m

Dec 31 2018US$343kn/a

US$143m

Sep 30 2018n/an/a

US$179m

Jun 30 2018n/an/a

US$120m

Mar 31 2018n/an/a

US$53m

Dec 31 2017US$283kn/a

US$13m

Compensation vs Market: Todd's total compensation ($USD6.22M) is above average for companies of similar size in the German market ($USD1.58M).

Compensation vs Earnings: Todd's compensation has been consistent with company performance over the past year.

CEO

Todd Davis (63 yo)

2yrs

Tenure

US$6,216,518

Compensation

Mr. Todd C. Davis, Ph.D. is a Director at NVN Liquidation Inc. He serves as an Independent Director of Channel Therapeutics Corporation (formerly known as Chromocell Therapeutics Corporation) since January...

Leadership Team

NamePositionTenureCompensationOwnership
Todd Davis
CEO & Director2yrsUS$6.22m0.42%
€ 8.7m
Octavio Espinoza
Chief Financial Officer2.1yrsUS$2.45m0.12%
€ 2.5m
Andrew Reardon
Chief Legal Officer & Secretary2.1yrsUS$2.34m0.12%
€ 2.5m
Paul Hadden
Senior Vice President of Investments & Business Developmentno datano datano data
Michael Jeong
Head of Investor Relationsno datano datano data
Todd Pettingill
Director of Corporate Developmentno datano datano data
Keith Marschke
Senior Vice President of Biology & Scientific Affairs6.9yrsno datano data
Vincent Antle
Senior Vice President of Technical Operations & QA - Capitsol6.9yrsno datano data
Patrick Lucy
Senior VP & CBO Protein Expression Businessno datano datano data
Karen Reeves
Senior VP of Investments & Head of Clinical Strategyless than a yearno datano data
Richard Baxter
Senior VP of Investment Operationless than a yearno datano data
Scott Plesha
CEO of Pelthos Therapeuticsless than a yearno datano data

2.0yrs

Average Tenure

57yo

Average Age

Experienced Management: LGDN's management team is considered experienced (2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Todd Davis
CEO & Director17.8yrsUS$6.22m0.42%
€ 8.7m
John Kozarich
Independent Chairman21.8yrsUS$361.70k0.23%
€ 4.7m
John LaMattina
Independent Director13.8yrsUS$329.20k0.15%
€ 3.1m
Stephen Sabba
Independent Director16.3yrsUS$341.70k0.15%
€ 3.2m
Jason Aryeh
Independent Director18.3yrsUS$339.20k0.43%
€ 9.0m
Shalendar Bhasin
Scientific Advisorno datano datano data
Jason Haas
Independent Director2.5yrsUS$346.70k0.022%
€ 455.5k
Nancy Gray
Independent Director7.3yrsUS$336.70k0.030%
€ 618.9k
Martine Zimmermann
Independent Director1.3yrsUS$467.87kno data

15.1yrs

Average Tenure

63.5yo

Average Age

Experienced Board: LGDN's board of directors are seasoned and experienced ( 15.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 04:44
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Ligand Pharmaceuticals Incorporated is covered by 22 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jasper HellwegArgus Research Company
Balaji PrasadBarclays
Balaji PrasadBarclays